

Resource Summary Report

Generated by [ASWG](#) on Aug 10, 2026

PE/Cyanine7 anti-mouse/human CD11b

RRID:AB_312798

Type: Antibody

Proper Citation

BioLegend Cat# 101215, RRID:AB_312798

Antibody Information

URL: http://antibodyregistry.org/AB_312798

Proper Citation: BioLegend Cat# 101215, RRID:AB_312798

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_312798

Vendor: BioLegend

Catalog Number: 101215

Alternative Catalog Numbers: 101216

Record Creation Time: 20250820T043350+0000

Record Last Update: 20250820T191900+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse/human CD11b.

No alerts have been found for PE/Cyanine7 anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 80 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Yu Y, et al. (2026) A stress-responsive neurovascular axis shapes skin immune accessibility. *iScience*, 29(3), 115122.

Yadav K, et al. (2026) Therapeutic targeting of GSK-3 β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ-2412, a novel sunitinib analogue. *British journal of pharmacology*, 183(15), 4196.

Yao J, et al. (2026) Activating an interleukin 4-FLT3-STAT6 axis in multipotent progenitors restores lymphopoiesis in inflammation and aging. *Immunity*, 59(7), 1843.

Bizzotto M, et al. (2026) Maternal-fetal type I interferon signaling drives TREM2 dysregulation and synaptic dysfunction in neurodevelopmental disorders. *Neuron*.

Noes-Holt G, et al. (2026) Recombinant dimeric PICK1 peptide inhibitors for long-term relief of chronic pain by AAV therapeutics. *Cell reports. Medicine*, 7(6), 102800.

Gao X, et al. (2026) Nanoparticles hijack calvarial immune cells for CNS drug delivery and stroke therapy. *Cell*, 189(5), 1341.

Shi X, et al. (2026) Tumor-immune-neural circuit disrupts energy homeostasis in cancer cachexia. *Cancer cell*, 44(5), 949.

Li H, et al. (2026) Nesfatin-1 Ameliorates Acute Pancreatitis by Inhibiting the Pyroptosis of Acinar Cells and Inflammation Mediated by Macrophages and Neutrophils. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(10), e71922.

Jiang R, et al. (2026) A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit. *Immunity*, 59(6), 1758.

Lim J, et al. (2026) Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity. *Science advances*, 12(19), eaea6842.

da Silva RAG, et al. (2026) Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. *Cell host & microbe*, 34(2), 245.

Tavares GA, et al. (2026) Macrophage-mediated refinement of the dural lymphatic regulates social behavior. *Neuron*.

Lecky DAJ, et al. (2025) Interferon- γ and IL-27 positively regulate type 1 regulatory T cell development during adaptive tolerance. *iScience*, 28(5), 112308.

Xu Y, et al. (2025) Type I interferon signaling controls the early hematopoietic expansion in response to β -glucan. *iScience*, 28(5), 112347.

Zhang X, et al. (2025) Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. *Nature metabolism*, 7(1), 102.

Wang Q, et al. (2025) ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. *Cell reports*, 44(10), 116314.

Sharma G, et al. (2025) IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation. *Cell reports*, 116330.

Lloyd EG, et al. (2025) SMAD4 and KRAS Status Shapes Cancer Cell-Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer. *Cancer research*, 85(8), 1368.

Nakayama Y, et al. (2025) Targeted labeling and depletion of alveolar macrophages using VeDTR mouse technology. *iScience*, 28(3), 111975.

Kim DH, et al. (2025) Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis. *Cell reports. Medicine*, 6(4), 102047.